QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances AI and Robotics Platform Toward Initial Commercial Deployment
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biotechnology company, reported continued progress on its proprietary AI platform and robotics integration as it nears initial commercial deployment. The Company has integrated approximately 28 million scientific abstracts into its PDAOAI platform and combined it with robotics developed alongside TechForce Robotics, enabling real-time, automated workflows designed to improve efficiency and support compliance in pharmaceutical development and manufacturing. To view the full press release, visit https://ibn.fm/2uitp About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and…